FY2025 · ended Dec 31, 2025 · Revenue $982.02M, +32.9% YoY · Filed Feb 19, 2026
Guardant Health, Inc. (GH) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $982.0 million and a net loss of $416.3 million. Free cash flow was -$233.1 million. As of Jun 30, 2026 it held $1.1 billion in cash and investments and $1.7 billion in total debt.
Revenue (TTM)
$1.18B
+42.7% vs year-ago TTM
Net income (TTM)
$-453.44M
-9.6% vs year-ago TTM
Operating cash flow (TTM)
$-185.19M
+22.4% vs year-ago TTM
Free cash flow (TTM)
$-240.72M
+11.4% vs year-ago TTM
EPS (TTM)
$-3.50
-4.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
131.17M
+6.3% vs prior year
Net cash
$-643.54M
as of Jun 30, 2026
Operating margin
-39.7%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- GH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1576280
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $982.0M | $739.0M | $563.9M | $449.5M | $373.7M |
| Operating income | -$437.2M | -$443.6M | -$564.7M | -$544.4M | -$411.0M |
| Net income | -$416.3M | -$436.4M | -$479.4M | — | — |
| Diluted EPS | -$3.32 | -$3.56 | -$4.28 | -$6.41 | -$4.00 |
| Operating cash flow | -$184.8M | -$239.9M | -$325.0M | -$309.5M | -$209.0M |
| Free cash flow | -$233.1M | -$274.9M | -$345.5M | -$386.9M | -$284.1M |
| Total assets | $2.0B | $1.5B | $1.8B | $1.6B | $2.2B |
| Total liabilities | $2.1B | $1.6B | $1.6B | $1.5B | $1.6B |
| Stockholders' equity | -$99.3M | -$139.6M | $158.7M | $60.2M | $645.0M |
| Cash and investments | $1.2B | $840.0M | $1.2B | $1.0B | $1.6B |
| Total debt | $1.7B | $193.5M | $213.8M | $231.9M | $238.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 1002 Guardant Health, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.